InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Trading2retire Free
11/21/16 9:29 PM
profile icon
stocktrademan Free
09/16/15 11:49 AM
profile icon
stocktrademan Free
06/11/15 3:14 PM

Zealand Pharma A/S (ZLDPF) RSS Feed

Followers
1
Posters
2
Posts (Today)
0
Posts (Total)
3
Created
06/11/15
Type
Free
Moderators
Zealand Pharma A/S Smedeland 36 Glostrup Copenhagen, 2600 Denmark Phone: 45 88 77 36 00 Fax: 45 88 77 38 98 Website: http://zealandpharma.com Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide medicines in Denmark. It offers Lyxumia (Lixisenatide), a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes. The company is also developing Lantus (LixiLan), which is in Phase III clinical trials for the treatment of type 2 diabetes; Danegaptide that is in Phase II clinical trials to treat cardiac reperfusion injuries; and Elsiglutide, a GLP-2 receptor agonist, which is in Phase IIb clinical trials for the treatment of chemotherapy-induced diarrhea in patients with colorectal cancer. In addition, it is developing ZP4207 that is in Phase I clinical trials to treat hypoglycemia in diabetes; and ZP2929, a dual acting glucagon/GLP-1 peptide receptor agonist, which is in Phase I clinical trials for the treatment of diabetes and/or obesity. The company has license agreements and partnerships with Sanofi S.A., Helsinn Healthcare S.A., Boehringer Ingelheim International GmbH, and Eli Lilly. Zealand Pharma A/S was founded in 1997 and is based in Copenhagen, Denmark.
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
ZLDPF Latest News
  • No Recent News Available for this company!
New Post